In this regard, stimulating regulatory function of infiltrating CD4+ T cells may act therapeutically in MS, PD and to a certain degree in ALS, while in AD and prion disease CD4+ T cells already seem regulatory and may benefit from a more pro-inflammatory T cell phenotype. This evidence concerns the gene CD4 and myeloid sarcoma.